 BRISBANE, Calif.--BUSINESS WIRE--Sangamo Therapeutics, Inc. Nasdaq: SGMO, a genomic medicine company, today reported recent business highlights and second quarter 2021 financial results. This is an exciting time at Sangamo, as we look forward to multiple clinical catalysts over the next several quarters representing potential near-term value drivers, while we continue to advance our promising preclinical pipeline focused on the emerging areas of CAR-Tregs and transcriptional regulation, re 